Publication details
SGLT2 inhibitory - glifloziny a kardiovaskulární a renální výsledky u diabetiků 2. typu
| Title in English | SGLT2 inhibitors - gliflozins and cardiovascular and renal effect in patients with diabets mellitus type 2 |
|---|---|
| Authors | |
| Year of publication | 2020 |
| Type | Article in Periodical |
| Magazine / Source | Hypertenze a kardiovaskulární prevence |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.hypertension.cz/sqlcache/hypertenze-cislo-1-2020.pdf |
| Keywords | gliflosins; cardiovascular effect; renal effect |
| Description | Diabetes mellitus type 2 is an epidemy of the 21st century. The Food and Drug Administration (FDA) announced that cardiovascular safety after peroral antidiabetics is a more important goal than the lowering of glycemia and this was the beginning of a large programme with antidiabetics and cardiovascular goals. The guidelines for heart failure accent the positive effect of SGLT-2 inhibitors with the indication IIa in 2016. Two important documents on SGLT2 and cardiovascular and renal outcomes were published in 2019 and both show a benefit of SGLT2. |